Cocrystal Pharma (NASDAQ:COCP – Get Free Report) and Aytu BioPharma (NASDAQ:AYTU – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.
Volatility and Risk
Cocrystal Pharma has a beta of 1.6, suggesting that its stock price is 60% more volatile than the S&P 500. Comparatively, Aytu BioPharma has a beta of 0.24, suggesting that its stock price is 76% less volatile than the S&P 500.
Institutional and Insider Ownership
6.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are owned by institutional investors. 39.4% of Cocrystal Pharma shares are owned by company insiders. Comparatively, 6.1% of Aytu BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Cocrystal Pharma and Aytu BioPharma”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cocrystal Pharma | $330,000.00 | 61.00 | -$8.83 million | ($0.76) | -1.38 |
| Aytu BioPharma | $57.57 million | 0.35 | -$14.25 million | ($1.66) | -1.11 |
Cocrystal Pharma has higher earnings, but lower revenue than Aytu BioPharma. Cocrystal Pharma is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current ratings and price targets for Cocrystal Pharma and Aytu BioPharma, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cocrystal Pharma | 1 | 0 | 1 | 0 | 2.00 |
| Aytu BioPharma | 2 | 0 | 2 | 0 | 2.00 |
Aytu BioPharma has a consensus price target of $14.50, indicating a potential upside of 685.91%. Given Aytu BioPharma’s higher probable upside, analysts clearly believe Aytu BioPharma is more favorable than Cocrystal Pharma.
Profitability
This table compares Cocrystal Pharma and Aytu BioPharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cocrystal Pharma | N/A | -207.47% | -123.33% |
| Aytu BioPharma | -24.76% | -56.54% | -13.14% |
Summary
Aytu BioPharma beats Cocrystal Pharma on 7 of the 13 factors compared between the two stocks.
About Cocrystal Pharma
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.
About Aytu BioPharma
Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.
Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
